CA2294579C - Liposome-entrapped polynucleotide composition and method - Google Patents

Liposome-entrapped polynucleotide composition and method Download PDF

Info

Publication number
CA2294579C
CA2294579C CA002294579A CA2294579A CA2294579C CA 2294579 C CA2294579 C CA 2294579C CA 002294579 A CA002294579 A CA 002294579A CA 2294579 A CA2294579 A CA 2294579A CA 2294579 C CA2294579 C CA 2294579C
Authority
CA
Canada
Prior art keywords
liposomes
polynucleotide
lipid
solvent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002294579A
Other languages
English (en)
French (fr)
Other versions
CA2294579A1 (en
Inventor
Theresa M. Allen
Darrin Stuart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of CA2294579A1 publication Critical patent/CA2294579A1/en
Application granted granted Critical
Publication of CA2294579C publication Critical patent/CA2294579C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002294579A 1997-06-23 1998-06-22 Liposome-entrapped polynucleotide composition and method Expired - Fee Related CA2294579C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5049097P 1997-06-23 1997-06-23
US60/050,490 1997-06-23
PCT/US1998/012937 WO1998058630A1 (en) 1997-06-23 1998-06-22 Liposome-entrapped polynucleotide composition and method

Publications (2)

Publication Number Publication Date
CA2294579A1 CA2294579A1 (en) 1998-12-30
CA2294579C true CA2294579C (en) 2007-10-09

Family

ID=21965541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294579A Expired - Fee Related CA2294579C (en) 1997-06-23 1998-06-22 Liposome-entrapped polynucleotide composition and method

Country Status (11)

Country Link
US (1) US6120798A (https=)
EP (1) EP1017365B1 (https=)
JP (1) JP2002508765A (https=)
AT (1) ATE255882T1 (https=)
AU (1) AU7983798A (https=)
CA (1) CA2294579C (https=)
DE (1) DE69820465T2 (https=)
DK (1) DK1017365T3 (https=)
ES (1) ES2212305T3 (https=)
TW (1) TWI225412B (https=)
WO (1) WO1998058630A1 (https=)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) * 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
JP2002536316A (ja) * 1999-02-08 2002-10-29 アルザ・コーポレーション リポソームサイズを調節する方法
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US20020146829A1 (en) * 2000-11-29 2002-10-10 Aventis Pharmaceuticals Products Inc. Neutral and anionic colloidal particles for gene delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer
KR100466254B1 (ko) * 2002-02-25 2005-01-14 한국과학기술원 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
EP1530465B2 (en) * 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2002953285A0 (en) * 2002-12-12 2003-01-02 Protech Research Pty Ltd Yeast treatment
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP2353389B1 (en) 2003-04-21 2015-11-04 Epeius Biotechnologies Corporation Compositions for treating disorders
EP1765294B1 (en) * 2004-05-12 2008-09-24 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
EP1970078A4 (en) 2006-01-11 2010-11-17 Kyowa Hakko Kirin Co Ltd COMPOSITION FOR INHIBITING A TARGET GENE IN AN EYEBORN AND REMEDY FOR ACAPIC DISEASE
EP2162552A4 (en) 2007-05-11 2010-06-30 Univ Johns Hopkins BIOMARKER FOR MELANOME
PL208054B1 (pl) * 2007-09-06 2011-03-31 Akademia Medyczna Im Piastow Śląskich We Wrocławiu Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
CA2710983A1 (en) * 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
CN105030809A (zh) 2008-08-01 2015-11-11 协和发酵麒麟株式会社 抑制靶基因表达的组合物
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411018A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
PL2474306T3 (pl) 2009-08-31 2017-06-30 Nanocarrier Co., Ltd. Kompozycja w postaci cząstek stałych i zawierająca ją kompozycja lecznicza
JP4653242B1 (ja) 2010-02-12 2011-03-16 ナノキャリア株式会社 粒子状医薬組成物
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
WO2011136369A1 (ja) 2010-04-28 2011-11-03 協和発酵キリン株式会社 カチオン性脂質
KR101773643B1 (ko) 2010-04-28 2017-08-31 교와 핫꼬 기린 가부시키가이샤 양이온성 지질
CN103119160B (zh) 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US9243246B2 (en) 2010-08-24 2016-01-26 Sirna Therapeutics, Inc. Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
JP5952197B2 (ja) 2011-01-19 2016-07-13 協和発酵キリン株式会社 標的遺伝子の発現を抑制する組成物
JP2013095755A (ja) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
US9631192B2 (en) 2011-11-17 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP)
AU2012340086A1 (en) 2011-11-17 2014-05-29 The Regents Of The University Of California Therapeutic RNA switches compositions and methods of use
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
KR20140111272A (ko) 2011-12-12 2014-09-18 교와 핫꼬 기린 가부시키가이샤 양이온성 지질의 조합을 함유하는 지질 나노 입자
US9556432B2 (en) 2012-01-10 2017-01-31 The Research Foundation For The State University Of New York Method of treating hyperlipidemia and atherosclerosis with miR-30C
AU2013237874B2 (en) 2012-03-29 2018-01-18 Translate Bio, Inc. Lipid-derived neutral nanoparticles
EP2852380A4 (en) 2012-05-23 2016-01-20 Univ Ohio State LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF
US10502737B2 (en) 2012-05-25 2019-12-10 The University Of Vermont And State Agriculture College Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
TW201408625A (zh) 2012-07-06 2014-03-01 Kyowa Hakko Kirin Co Ltd 陽離子性脂質
CA2878314A1 (en) 2012-07-16 2014-01-23 Kyowa Hakko Kirin Co., Ltd. Rnai pharmaceutical composition for suppressing expression of kras gene
JP6000033B2 (ja) * 2012-09-18 2016-09-28 株式会社ピカソ美化学研究所 内包物質に耐熱性を与えたリポソーム及びその製造方法
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
US11174484B2 (en) 2015-11-10 2021-11-16 B. G. Negev Technologies And Applications Ltd., At Ben- Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
US11998540B2 (en) 2015-12-11 2024-06-04 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
CA3009131C (en) 2015-12-25 2024-06-04 Kyowa Hakko Kirin Co., Ltd. Compounds as cationic lipids and their use in nucleic acid delivery compositions
JP7522038B2 (ja) 2018-04-06 2024-07-24 ザ チルドレンズ メディカル センター コーポレーション 体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法
EP3628309A1 (en) 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
IL294441A (en) * 2019-12-31 2022-09-01 Fred Hutchinson Cancer Center Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
JP2023530234A (ja) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物を治療するための組成物および方法
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
CA3234809A1 (en) 2021-10-20 2023-04-27 Steven Goldman Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
EP4658294A2 (en) 2023-02-02 2025-12-10 University of Rochester Competitive replacement of glial cells
WO2024226499A1 (en) 2023-04-24 2024-10-31 The Broad Institute, Inc. Compositions and methods for modifying fertility
WO2025090427A1 (en) 2023-10-23 2025-05-01 University Of Rochester Glial-targeted relief of hyperexcitability in neurodegenerative diseases
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5976567A (en) * 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
FR2751222B1 (fr) * 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique

Also Published As

Publication number Publication date
CA2294579A1 (en) 1998-12-30
DK1017365T3 (da) 2004-03-29
HK1025906A1 (en) 2000-12-01
EP1017365A1 (en) 2000-07-12
JP2002508765A (ja) 2002-03-19
WO1998058630A1 (en) 1998-12-30
EP1017365B1 (en) 2003-12-10
AU7983798A (en) 1999-01-04
TWI225412B (en) 2004-12-21
ATE255882T1 (de) 2003-12-15
DE69820465T2 (de) 2004-09-16
DE69820465D1 (de) 2004-01-22
US6120798A (en) 2000-09-19
ES2212305T3 (es) 2004-07-16

Similar Documents

Publication Publication Date Title
CA2294579C (en) Liposome-entrapped polynucleotide composition and method
Monck et al. Stabilized plasmid–lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection
Wheeler et al. Stabilized plasmid-lipid particles: construction and characterization
Maurer et al. Lipid-based systems for the intracellular delivery of genetic drugs
Stuart et al. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability
EP0955999B1 (en) Novel liposome complexes for increased systemic delivery
Lasic Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo
US6835395B1 (en) Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
Fenske et al. [3] Stabilized plasmid-lipid particles: A systemic gene therapy vector
WO1998007408A9 (en) Novel liposome complexes for increased systemic delivery
JP2002528381A (ja) 脂質媒介式の遺伝子及び化合物導入を利用する化合物に対する細胞の感作
KR100723852B1 (ko) 핵산 및 약물 전달용 중성-양이온성 지질
US7005140B2 (en) Lipid particles having asymmetric lipid coating and method of preparing same
CA2342292A1 (en) Condensed plasmid-liposome complex for transfection
CN1616665B (zh) 定向脂质体基因送递
WO2014037436A1 (en) Lipid assemblies comprising anionic lysolipids and use thereof
Palmer et al. Transfection properties of stabilized plasmid–lipid particles containing cationic PEG lipids
PL208054B1 (pl) Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
Bartsch et al. Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo
WO2024167924A2 (en) Multi-functional lipid nanoparticles and uses thereof
Yamauchi et al. Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes
HK1025906B (en) Liposome-entrapped polynucleotide composition and method
WO1999015206A1 (en) Methods for preparing lipids/polynucleotide transfection complexes
Palmer Development of stabilized plasmid lipid particles as intracellular gene delivery vehicles
Wong DNA-triggered release liposomes: a pharmaceutical strategy for improving the tumor exposure of chemotherapeutic agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed